Expression of a dominant-negative type II transforming growth factor beta (TGF-beta) receptor in the epidermis of transgenic mice blocks TGF-beta-mediated growth inhibition.
To determine whether a functional type II receptor of transforming growth factor beta (TGF-beta) is required to mediate the growth inhibitory effect of TGF-beta on the skin in vivo, we have generated transgenic mice that overexpress a dominant negative-type II TGF-beta receptor (delta beta RII) in the epidermis. The delta beta RII mice exhibited a thickened and wrinkled skin, and histologically the epidermis was markedly hyperplastic and hyperkeratotic. In vivo labeling with BrdUrd showed a 2.5-fold increase in the labeling index over controls, with labeled nuclei occurring in both basal and suprabasal cells of transgenic epidermis. In heterozygotes, this skin phenotype gradually diminished, and by 10-14 days after birth the transgenic mice were indistinguishable from their normal siblings. However, when F1 mice were mated to homozygosity, perinatal lethality occurred due to the severe hyperkeratotic phenotype, which restricted movement. Cultured primary keratinocytes from delta beta RII mice also exhibited an increased rate of growth in comparison with nontransgenic controls, and were resistant to TGF-beta-induced growth inhibition. These data document the role of the type II TGF-beta receptor in mediating TGF-beta-induced growth inhibition of the epidermis in vivo and in maintenance of epidermal homeostasis.
Wang
X J
XJ
Department of Cell Biology, Baylor College of Medicine, Houston, TX 77030, USA.
Greenhalgh
D A
DA
Bickenbach
J R
JR
Jiang
A
A
Bundman
D S
DS
Krieg
T
T
Derynck
R
R
Roop
D R
DR
D000595:Amino Acid Sequence; D000818:Animals; D000831:Animals, Newborn; D002455:Cell Division / Q000187:drug effects; D002478:Cells, Cultured; D004817:Epidermis / Q000187:drug effects / Q000473:pathology / Q000502:physiology*; D000939:Epitopes / Q000737:chemistry; D005260:Female; D016259:Genes, myc; D006801:Humans; D006984:Hypertrophy; D015603:Keratinocytes / Q000166:cytology* / Q000187:drug effects / Q000502:physiology*; D007642:Keratosis / Q000235:genetics; D008297:Male; D051379:Mice; D008813:Mice, Inbred ICR; D008815:Mice, Inbred Strains; D008822:Mice, Transgenic; D008940:Mitotic Index; D017346:Protein Serine-Threonine Kinases; D016271:Proto-Oncogene Proteins c-myc / Q000096:biosynthesis; D000077294:Receptor, Transforming Growth Factor-beta Type II; D018125:Receptors, Transforming Growth Factor beta / Q000096:biosynthesis*; D012867:Skin / Q000473:pathology; D015595:Skin Aging; D012879:Skin Physiological Phenomena; D016212:Transforming Growth Factor beta / Q000494:pharmacology*
D000939:Epitopes; D016271:Proto-Oncogene Proteins c-myc; D018125:Receptors, Transforming Growth Factor beta; D016212:Transforming Growth Factor beta; D017346:Protein Serine-Threonine Kinases; D000077294:Receptor, Transforming Growth Factor-beta Type II